Evidence map›Paper›PMID 35202463›Full record

ReviewBrain : a journal of neurology2022

Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.

Jared S Katzeff, Fiona Bright, Katherine Phan, Jillian J Kril, Lars M Ittner, Michael Kassiou, John R Hodges, Olivier Piguet, Matthew C Kiernan, Glenda M Halliday and 1 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.International journal of molecular sciences · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jared S KatzeffBrain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
Fiona BrightSchool of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.
Katherine PhanBrain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
Jillian J KrilSchool of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.
Lars M IttnerDementia Research Centre, Macquarie Medical School, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0001-6738-3825
Michael KassiouSchool of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
John R HodgesBrain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
Olivier PiguetBrain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
Matthew C KiernanBrain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
Glenda M HallidayBrain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0003-0422-8398
Woojin Scott KimBrain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.ORCID 0000-0002-4707-933X
The University of Sydney · AUMacquarie University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frontotemporal dementia refers to a group of neurodegenerative disorders characterized by behaviour and language alterations and focal brain atrophy. Amyotrophic lateral sclerosis is a rapidly progressing neurodegenerative disease characterized by loss of motor neurons resulting in muscle wasting and paralysis. Frontotemporal dementia and amyotrophic lateral sclerosis are considered to exist on a disease spectrum given substantial overlap of genetic and molecular signatures. The predominant genetic abnormality in both frontotemporal dementia and amyotrophic lateral sclerosis is an expanded hexanucleotide repeat sequence in the C9orf72 gene. In terms of brain pathology, abnormal aggregates of TAR-DNA-binding protein-43 are predominantly present in frontotemporal dementia and amyotrophic lateral sclerosis patients. Currently, sensitive and specific diagnostic and disease surveillance biomarkers are lacking for both diseases. This has impeded the capacity to monitor disease progression during life and the development of targeted drug therapies for the two diseases. The purpose of this review is to examine the status of current biofluid biomarker discovery and development in frontotemporal dementia and amyotrophic lateral sclerosis. The major pathogenic proteins implicated in different frontotemporal dementia and amyotrophic lateral sclerosis molecular subtypes and proteins associated with neurodegeneration and the immune system will be discussed. Furthermore, the use of mass spectrometry-based proteomics as an emerging tool to identify new biomarkers in frontotemporal dementia and amyotrophic lateral sclerosis will be summarized.

Indexed as

Amyotrophic Lateral SclerosisFrontotemporal DementiaNeurodegenerative DiseasesPick Disease of the BrainC9orf72 ProteinDNA Repeat ExpansionHumansC9orf72 Proteinamyotrophic lateral sclerosisbiomarkersfrontotemporal dementianeurofilamentproteomics

Identifiers

PMID35202463
PMCPMC9166557
OpenAlexW4213428434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.